Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Completed · Phase 3 · NCT04260698
Conditions: Hematological Malignancies
At a glance
- Research payments reported, 2025
- $69,178
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Gamida Cell ltd
- Tested
- omidubicel (biological)
- Dates
- Started 2020-07-08; completion 2025-05-08
- Results posted
- Yes
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
From ClinicalTrials.gov, last updated 2026-06-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Gamida Cell Inc. reported $69,178 in research payments for this study in 2025 (5 payments).
Products named: Omisirge
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Andrew R. Rezvani, MD Medical Oncology · Stanford, CA
- Gary J. Schiller, MD Hematology & Oncology · Los Angeles, CA
- Mitchell Horwitz Infectious Disease · Durham, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University Medical Center $33,900
- Resnick Neuropsychiatric Hospital at UCLA, CA $20,726
- Stanford University $14,552
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.